background
influenza
virus
caus
seriou
infect
prevent
treat
use
vaccin
antivir
agent
respect
vaccin
effect
number
limit
influenza
strain
resist
current
avail
antiinfluenza
drug
increasingli
isol
necessit
explor
novel
antiinfluenza
therapi
methodologyprincip
find
investig
potenti
aurintricarboxyl
acid
ata
potent
inhibitor
nucleic
acid
process
enzym
protect
madindarbi
canin
kidney
cell
influenza
infect
found
neutral
red
assay
ata
protect
rtpcr
elisa
respect
confirm
ata
reduc
viral
replic
releas
furthermor
pretreat
cell
ata
fail
inhibit
viral
replic
preincub
viru
ata
effect
reduc
viral
titer
suggest
ata
may
elicit
inhibitori
effect
directli
interact
viru
electron
microscopi
reveal
ata
induc
viral
aggreg
cell
surfac
prompt
us
determin
ata
could
inhibit
neuraminidas
ata
found
compromis
activ
virusderiv
recombin
neuraminidas
moreov
oseltamivirresist
strain
also
found
sensit
ata
final
observ
addit
protect
valu
infect
cell
simultan
treat
ata
amantadin
hydrochlorid
antiinfluenza
drug
inhibit
channel
influenza
viru
conclusionssignific
collect
data
suggest
ata
potent
antiinfluenza
agent
directli
inhibit
neuraminidas
could
effect
antivir
compound
use
combin
amantadin
hydrochlorid
influenza
virus
caus
highli
contagi
respiratori
tract
infect
frequent
mutat
influenza
gene
particularli
encod
surfac
hemagglutinin
ha
neuraminidas
na
protein
allow
viru
evad
host
immun
system
give
rise
new
infecti
strain
respons
annual
epidem
associ
signific
morbid
mortal
recent
infect
human
highli
pathogen
avian
swineorigin
influenza
virus
reinforc
notion
emerg
novel
viru
strain
unpredict
capabl
threaten
worldwid
popul
given
magnitud
flu
pandem
threat
global
popul
crucial
mani
prevent
treatment
option
possibl
vaccin
either
inactiv
live
attenu
virus
offer
best
protect
influenza
infect
induc
neutral
antibodi
ha
na
antigen
specif
influenza
strain
howev
current
vaccin
ideal
must
develop
valid
annual
lengthi
manufactur
distribut
time
short
shelf
live
importantli
failur
accur
anticip
circul
strain
result
reduc
efficaci
protect
vaccin
drawback
associ
interpandem
vaccin
would
drastic
exacerb
event
futur
pandem
therefor
crucial
investig
novel
therapeut
prevent
antiinfluenza
agent
present
two
class
antivir
agent
develop
approv
prophylaxi
treatment
season
influenza
infect
first
class
block
influenza
protein
form
hydrogen
ion
channel
requir
effici
uncoat
incom
virus
second
class
inhibit
influenza
na
requir
effici
releas
viral
particl
infect
cell
howev
resist
blocker
na
inhibitor
report
extens
aurintricarboxyl
acid
ata
polyaromat
carboxyl
acid
deriv
inhibit
nucleas
nucleic
acid
process
enzym
ata
shown
inhibit
replic
human
immunodefici
vesicular
stomat
virus
recent
found
ata
could
inhibit
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
vaccinia
viru
report
ata
substanti
inhibit
replic
sever
strain
influenza
virus
onetyp
b
viru
tissu
cultur
moder
cytotox
investig
combin
effect
ata
amantadin
hydrochlorid
blocker
replic
influenza
virus
final
found
ata
inhibit
influenza
neuraminidas
possibl
elucid
antiinfluenza
mechan
action
madindarbi
canin
kidney
mdck
cell
atcc
obtain
american
type
cultur
collect
manassa
va
usa
grown
modifi
minimum
essenti
medium
modifi
mem
contain
earl
balanc
salt
supplement
mm
lglutamin
gl
sodium
bicarbon
ph
mm
nonessenti
amino
acid
mm
sodium
pyruv
heatinactiv
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
invitrogen
carlsbad
ca
humidifi
atmospher
co
virus
amplifi
titrat
mdck
cell
store
use
aurintricarboxyl
acid
ata
amantadin
hydrochlorid
ah
acid
naa
sigma
st
loui
mo
usa
stock
solut
drug
prepar
immedi
use
dimethyl
sulfoxid
dmso
filter
use
nm
filter
neutral
red
vital
dye
incorpor
vacuol
viabl
cell
detect
spectrophotometr
use
determin
cell
viabil
vitro
efficaci
toxic
antivir
compound
previous
determin
measur
uptak
neutral
red
therefor
neutral
red
assay
kit
sigma
st
loui
usa
use
assess
cytotox
antivir
potenti
ata
accord
manufactur
instruct
determin
ata
cytotox
confluent
mdck
monolay
plate
wash
twice
pb
expos
ata
ml
postadsorpt
medium
h
co
determin
inhibitori
potenti
ata
alon
combin
ah
inoculum
aspir
follow
viral
adsorpt
cell
wash
twice
pb
incub
ml
postadsorpt
medium
contain
ata
andor
ah
h
co
dmso
concentr
treatment
h
neutral
red
dye
ad
medium
well
concentr
incub
h
medium
remov
cell
fix
rins
cacl
formaldehyd
incorpor
dye
solubil
ml
acet
acid
ethanol
cell
incub
room
temperatur
min
gentl
agit
absorb
measur
nm
synergi
tm
multimod
micropl
reader
mdck
cell
also
evalu
microscop
examin
cytopath
effect
cpe
result
ata
cytotox
present
percentag
absorb
atatr
cell
rel
untreat
control
ata
andor
ah
protect
result
express
percentag
absorb
treat
untreat
infect
cell
rel
untreat
uninfect
control
concentr
drug
requir
inhibit
cpe
induc
ec
determin
total
rna
extract
cell
h
follow
infect
influenza
treatment
ata
use
rneasi
mini
kit
qiagen
inc
valencia
ca
extract
rna
treat
dnase
ambion
inc
streetsvil
ontario
canada
singl
step
revers
transcriptionpcr
perform
use
titan
one
tube
rtpcr
kit
roch
appli
scienc
mannheim
germani
accord
manufactur
instruct
influenza
nucleoprotein
rna
amplifi
ng
rna
total
reaction
volum
ml
use
forward
revers
primer
respect
revers
transcript
perform
min
initi
denatur
min
two
amplif
step
perform
first
step
consist
cycl
denatur
sec
anneal
sec
elong
sec
second
step
consist
cycl
cycl
condit
sec
ad
elong
step
cycl
final
extens
min
ml
rtpcr
product
load
agaros
gel
visual
sybr
green
stain
uv
exposur
extracellular
influenza
antigen
detect
cell
cultur
supernat
use
commerci
elisa
kit
takara
bio
inc
otsu
shiga
japan
cultur
media
remov
h
cell
infect
viru
treat
ata
ah
supernat
clarifi
centrifug
min
sampl
posit
control
standard
dilut
diluent
lysi
buffer
ad
individu
well
mlwell
incub
h
immobil
monoclon
antibodi
direct
influenza
nucleoprotein
np
wash
three
time
pb
contain
sampl
incub
biotinyl
rabbit
polyclon
antiinfluenza
viru
antibodi
h
follow
three
wash
streptavidinophenylenediamin
dihydrochlorid
conjug
ad
well
plate
incub
min
well
wash
four
time
incub
substrat
solut
consist
hydrogen
peroxid
tetramethylbenzidin
room
temperatur
min
reaction
stop
addit
n
h
prior
absorb
read
nm
use
synergi
tm
multimod
micropl
reader
viral
abund
calcul
hemagglutin
ha
unit
standard
curv
use
posit
control
known
ha
content
one
ha
unit
equal
quantiti
viru
requir
complet
aggreg
erythrocyt
ha
assay
ml
vv
commerci
elisa
kit
certain
limit
employ
antinucleoprotein
captur
antibodi
coat
plate
antiinfluenza
viral
protein
total
influenza
viral
protein
includ
hemagglutinin
detect
antibodi
solut
sandwich
elisa
hemagglutinin
vari
strain
strain
term
amino
acid
sequenc
ratio
viral
protein
one
directli
compar
ha
unit
two
differ
strain
therefor
present
result
percentag
ha
unit
treat
infect
sampl
rel
untreat
infect
control
strain
confluent
cell
well
plate
wash
twice
pb
inocul
ml
mem
contain
h
uc
inoculum
aspir
cell
wash
twice
pb
treat
dmso
mgml
ata
mgml
ah
mgml
naa
h
cell
scrape
well
collect
centrifug
min
supernat
transfer
new
tube
cell
lyse
cycl
freez
thaw
supernat
lysat
subject
plaqu
assay
describ
previous
determin
extracellular
cellassoci
viru
titer
yield
upon
ata
treatment
confluent
cell
monolay
well
plate
incub
ml
supernat
lysat
h
inoculum
remov
cell
wash
pb
overlaid
mainten
mem
medium
contain
agaros
bsa
mm
lglutamin
gl
sodium
bicarbon
ph
mm
nonessenti
amino
acid
mm
sodium
pyruv
uml
penicillin
mgml
streptomycin
mgml
tpcktreat
trypsin
incub
day
humidifi
atmospher
co
cell
either
stain
neutral
red
directli
fix
formaldehyd
follow
stain
crystal
violet
plaqu
count
nc
ny
wsn
influenza
b
virus
concentr
plaqu
form
unit
pfu
incub
ata
min
virusata
mixtur
transfer
confluent
cell
monolay
plate
incub
h
subject
plaqu
assay
describ
previous
confluent
cell
well
plate
inocul
viru
h
treat
dmso
mgml
ata
mgml
ah
postadsorpt
medium
h
cell
scrape
well
centrifug
min
medium
discard
cell
incub
icecold
fix
glutaraldehyd
cacodyl
buffer
ph
min
gentl
agit
cell
pellet
centrifug
min
room
temperatur
cell
pellet
resuspend
ml
fix
rins
cacodyl
buffer
twice
min
postfix
osmium
tetroxid
h
fix
cell
wash
water
twice
min
dehydr
increas
concentr
ethanol
embed
spurr
resin
thin
nm
section
cut
ultramicrotom
counter
stain
uranyl
acet
lead
citrat
section
view
photograph
jeol
transmiss
electron
microscop
nastarh
influenza
neuraminidas
inhibitor
resist
detect
kit
appli
biosystem
foster
citi
ca
usa
use
measur
inhibit
na
activ
describ
previous
briefli
serial
dilut
ata
ah
naa
rang
mgml
mgml
prepar
nastar
assay
buffer
ie
ten
ml
nastar
substrat
dilut
assay
buffer
final
concentr
mm
ad
mixtur
opaqu
solidwhit
plate
reaction
incub
min
gentl
agit
ml
nastar
acceler
ad
well
chemiluminesc
signal
measur
rate
secwel
synergi
tm
multimod
micropl
reader
curv
construct
plot
percentag
na
activ
chemiluminesc
signal
presenc
inhibitor
rel
activ
control
na
without
inhibitor
concentr
inhibitor
use
determin
drug
concentr
requir
reduc
na
activ
control
na
activ
ic
data
express
mean
standard
deviat
na
inhibit
assay
ic
calcul
determin
use
nonlinear
curv
fit
graphpad
prism
version
statist
analysi
conduct
use
either
oneway
twoway
anova
appropri
adjust
multipl
comparison
bonferroni
comparison
post
test
use
p
valu
regard
statist
signific
other
report
ata
inhibit
certain
rna
virus
therefor
postul
ata
may
also
inhibit
replic
influenza
virus
evalu
abil
ata
protect
mdck
cell
influenza
infect
cell
inocul
differ
influenza
viral
strain
incub
presenc
absenc
ata
mgml
day
microscop
examin
reveal
drastic
reduct
influenzainduc
cpe
follow
treatment
ata
data
shown
viabil
mdck
cell
infect
influenza
virus
incub
presenc
absenc
ata
assay
incorpor
neutral
red
dye
infect
cell
treat
ata
increas
neutral
red
uptak
fig
confirm
ata
significantli
protect
mdck
cell
influenza
infect
ata
concentr
caus
cytotox
cc
mdck
cell
determin
assay
neutral
red
uptak
found
mgml
fig
shown
fig
ata
prevent
infect
mdck
cell
dosedepend
manner
minimum
effect
dose
mgml
requir
protect
cell
ec
therefor
therapeuticselect
index
si
refer
ratio
amount
ata
exert
therapeut
effect
amount
caus
toxic
mdck
cell
examin
prophylact
potenti
ata
influenza
infect
mdck
cell
expos
ata
h
prior
viral
infect
cell
viabil
assess
measur
neutral
red
uptak
found
preexpos
mdck
cell
ata
h
prior
infect
protect
cell
virusinduc
cpe
data
shown
collect
data
suggest
ata
potent
antiinfluenza
agent
rel
low
toxic
tissu
cultur
demonstr
si
valu
examin
whether
protect
effect
ata
due
inhibit
viral
replic
level
influenza
nucleoprotein
rna
isol
mdck
cell
determin
reversetranscript
pcr
cell
infect
low
level
b
actin
rna
fig
like
due
cell
death
howev
level
bactin
rna
remain
rel
constant
upon
exposur
increas
ata
concentr
treatment
ata
determin
ata
treatment
also
reduc
level
influenza
virus
releas
medium
supernat
atatr
infect
cell
cultur
subject
analys
viral
protein
elisa
shown
fig
treatment
cell
ata
dramat
reduc
viru
yield
dose
mgml
mgml
ata
reduc
abund
nc
ny
respect
statist
signific
differ
two
virus
nc
yet
viru
slightli
resist
ata
treatment
see
addit
discuss
sinc
elisa
measur
infecti
noninfecti
particl
determin
whether
ata
treatment
specif
reduc
abund
infecti
particl
cell
infect
expos
ata
previous
establish
antiinfluenza
agent
ah
blocker
naa
neuraminidas
inhibitor
viru
titr
cell
lysat
supernat
fraction
determin
plaqu
assay
ata
treatment
significantli
reduc
cellassoci
extracellular
viru
yield
compar
either
ah
naa
tabl
moreov
ata
includ
mainten
media
plaqu
reduct
assay
cell
infect
either
influenza
b
virus
reduc
number
size
plaqu
data
shown
taken
togeth
data
suggest
ata
potent
inhibitor
influenza
b
virus
upon
demonstr
ata
protect
mdck
cell
influenza
infect
reduc
viral
replic
releas
sought
investig
mechan
underli
antiinfluenza
activ
ata
protect
influenzainfect
mdck
cell
enhanc
simultan
treatment
two
antivir
act
via
differ
mechan
therefor
mdck
cell
infect
influenza
treat
concomitantli
ata
agent
known
antivir
mechan
shown
fig
cytopath
effect
induc
influenza
virus
mdck
cell
reduc
significantli
concomit
treatment
ata
ah
compar
either
treatment
alon
protect
effect
combin
ata
ah
treatment
confirm
quantit
detect
influenza
virus
present
cultur
supernat
elisa
fig
notabl
cotreat
ata
ah
virtual
abolish
viru
product
media
sinc
ah
effect
antiinfluenza
properti
target
viral
protein
prevent
effici
uncoat
incom
viral
particl
conclud
inhibit
influenza
replic
releas
ata
mediat
distinct
mechan
begin
elucid
ata
protect
cell
influenza
infect
investig
whether
ata
elicit
inhibitori
action
directli
viru
previou
experi
consequ
ata
examin
viral
infect
determin
ata
inhibit
influenza
virus
directli
mdck
cell
infect
virus
preincub
ata
subject
plaqu
assay
shown
fig
preincub
influenza
b
virus
ata
reduc
number
plaqu
protect
cell
suggest
ata
inactiv
viral
protein
directli
gain
insight
ata
directli
inhibit
influenza
viru
mdck
cell
infect
treat
ata
ah
examin
elect
microscopi
compar
untreat
cell
incub
ah
ata
treatment
found
induc
viral
aggreg
cell
surfac
fig
find
similar
previou
observ
investiga
tor
work
na
inhibitor
nadefect
particl
studi
na
believ
prevent
aggreg
progeni
virus
surfac
infect
cell
therefor
postul
ata
elicit
viral
aggreg
inhibit
enzymat
activ
na
address
question
test
effect
ata
na
activ
compar
effect
naa
known
na
inhibitor
expect
naa
inhibit
na
activ
low
ic
valu
ah
show
inhibit
data
shown
found
ata
inhibit
na
activ
concentrationdepend
manner
virus
mark
differ
among
shown
fig
ata
inhibit
na
activ
influenza
nc
ny
b
virus
ic
mgml
mgml
mgml
mgml
respect
addit
ata
significantli
inhibit
enzymat
activ
two
recombin
na
protein
fig
ic
mgml
mgml
respect
next
test
effect
ata
common
oseltamivirresist
viral
strain
ie
wsn
viru
substitut
comparison
parent
wildtyp
wsn
viru
shown
fig
ata
inhibit
replic
wsn
virus
doserespons
fashion
ic
valu
obtain
ata
inhibit
wsn
virus
mgml
mgml
respect
fig
although
mutat
significantli
increas
ata
ic
compar
wildtyp
viru
ata
remain
potent
inhibitor
wildtyp
wsn
oseltamivirresist
wsn
compar
increas
ic
oseltamivir
inhibit
mutant
influenza
viru
highli
contagi
result
signific
morbid
mortal
mass
vaccin
suscept
popul
best
approach
prevent
influenza
infect
propens
mutat
gene
reassort
result
occasion
emerg
novel
unpredict
influenza
viru
strain
give
rise
global
influenza
pandem
current
tripl
reassort
swineorigin
influenza
viru
sinc
consider
time
requir
develop
distribut
vaccin
novel
influenza
strain
rapidli
spread
global
vaccin
avail
mass
immun
given
potenti
widespread
influenza
infect
crucial
understand
improv
treatment
diseas
antivir
drug
current
use
blocker
amantadin
rimantidin
na
inhibitor
oseltamivir
zanamivir
reduc
durat
flu
symptom
howev
singl
mutat
render
influenza
virus
resist
antivir
drug
blocker
na
inhibitor
drugresist
influenza
strain
isol
patient
receiv
antivir
treatment
find
necessit
explor
novel
antiinfluenza
agent
other
observ
ata
inhibit
varieti
virus
observ
prompt
us
determin
effect
ata
replic
influenza
viru
report
present
data
clearli
demonstr
ata
protect
mdck
cell
infect
influenza
strain
specif
rtpcr
elisa
analys
indic
ata
treatment
reduc
intracellular
accumul
viral
genom
releas
influenza
virus
media
magnitud
inhibit
determin
product
infecti
viral
particl
found
least
log
compar
log
reduct
either
naa
ah
tabl
although
ata
report
antivir
activ
human
immunodefici
viru
vesicular
stomat
viru
sarscov
vaccinia
viru
mechan
ata
inhibit
divers
group
virus
remain
larg
undefin
variou
biolog
activ
ascrib
ata
character
inhibitor
nucleic
acid
process
enzym
nucleas
kinas
jakstat
pathway
describ
antiapoptot
factor
insulinlik
growth
factor
varieti
cellular
activ
associ
ata
complic
elucid
antivir
mechan
previous
propos
ata
inhibit
influenza
virus
compromis
viral
rnadepend
polymeras
present
evid
suggest
antivir
activ
ata
could
attribut
inhibit
viral
neuraminidas
specif
first
observ
aggreg
viral
particl
surfac
cell
reminisc
previou
report
investig
studi
na
inhibitor
nadefect
virus
observ
led
us
conduct
cellfre
na
assay
reveal
ata
substanti
inhibit
enzymat
activ
viral
recombin
na
differ
magnitud
inhibit
nc
ny
virus
infect
cultur
fig
fulli
understood
interestingli
mark
differ
observ
neuraminidas
inhibit
test
ie
ic
three
strain
fig
reason
discrep
tissu
cultur
studi
vitro
enzymat
studi
still
unclear
plausibl
vitro
enzymat
studi
may
accur
reflect
event
live
cell
cultur
moreov
ic
oseltamivirresist
strain
increas
fig
think
ata
still
potent
inhibitor
oseltamivirresist
strain
compar
oseltamivir
inhibit
mutant
increas
ic
need
would
interest
investig
potenti
ata
resist
mutant
respect
na
amino
acid
mutat
prepar
manuscript
note
hung
et
al
also
report
ata
protect
cell
varieti
viru
strain
vitro
inhibit
na
cellfre
assay
studi
ic
select
index
higher
report
hung
et
al
suspect
discrep
might
due
differ
experiment
condit
two
group
demonstr
viral
na
activ
compromis
ata
possibl
ata
also
target
viral
cellular
protein
exert
antiinfluenza
activ
addit
studi
requir
answer
question
sinc
inhibit
influenza
ata
ah
mediat
two
distinct
mechan
surpris
observ
addit
effect
upon
simultan
treatment
compound
recent
advisori
committe
immun
practic
acip
recommend
use
amantadin
rimantidin
treat
influenza
infect
due
increas
evolut
blockerresist
influenza
strain
although
influenza
strain
resist
na
inhibitor
less
preval
resist
oseltamivir
also
report
suggest
use
singl
class
antivir
may
limit
protect
valu
futur
influenza
treatment
strategi
like
includ
combin
medic
notabl
combin
use
blocker
na
inhibitor
provid
addit
protect
influenza
infect
compar
either
treatment
alon
mice
infect
lethal
dose
either
amantadinesensit
amantadineresist
influenza
protect
cotreat
amantadin
oseltamivir
treat
one
drug
found
simultan
treatment
ata
ah
significantli
protect
mdck
cell
influenza
dramat
reduc
abund
influenza
particl
releas
medium
toxic
ata
need
evalu
anim
studi
show
ata
associ
rel
low
toxic
tissu
cultur
si
around
although
vivo
toxic
studi
ata
rather
limit
previou
research
hamster
shown
infus
ata
well
toler
dose
mgkghour
week
also
jan
balzarini
et
al
found
singl
ata
dose
mgkg
nmri
mice
associ
ld
mice
median
life
span
day
upon
intraperiton
administr
mgkgday
intratrach
inhal
show
singl
dose
ata
high
mg
kg
toler
well
mice
howev
therapeut
toxic
dose
would
determin
anim
studi
current
investig
laboratori
short
ata
na
inhibitor
may
prove
valuabl
inclus
current
arsen
antiinfluenza
agent
data
present
provid
compel
evid
studi
antiinfluenza
potenti
ata
anim
model
